Atara Biotherapeutics Q1 Earnings Show Lower Than Expected GAAP EPS and Revenue Figures

Thursday, 28 March 2024, 12:43

Atara Biotherapeutics released their Q1 earnings report, revealing a GAAP EPS of -$0.56, missing expectations by $0.03, along with revenue of $4.25M, falling short by $10.01M. The company's financial performance in the first quarter was below market projections, indicating potential challenges ahead. Investors may need to reevaluate their positions in light of Atara Biotherapeutics' weaker earnings numbers.
LivaRava Finance Meta Image
Atara Biotherapeutics Q1 Earnings Show Lower Than Expected GAAP EPS and Revenue Figures

Atara Biotherapeutics Q1 Earnings Overview

Atara Biotherapeutics recently disclosed its financial performance for the first quarter of the year, showing significant discrepancies in GAAP EPS and revenue figures.

Key Highlights:

  • GAAP EPS: Recorded at -$0.56, missing estimates by $0.03.
  • Revenue: Reported as $4.25M, falling short by a substantial $10.01M.

These disappointing results indicate potential challenges for the company moving forward, prompting investors to reconsider their positions.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe